A company who are committed to changing the way vaccines are developed and taken are seeking a Formulation Scientist. They achieve this through a platform technology which means vaccines can be taken as a capsule. This is a step change technology that means vaccines are not only thermally stable but more effective, can be delivered globally, and developed quickly. Their success includes a COVID therapy as well as a Zika therapy and other new targets under investigation as they as seek to exploit their technology fully.
.The Opportunity:
They need a Formulation Scientist to be a part of their dynamic team scaling up the technology as it progresses from R&D, through clinical trials to commercial scale manufacture. There is particular emphasis on Spray Drying because this is a crucial part of the scale up process and a new technology introduced to the laboratories.
The key responsibilities are:
- Contribute to the design of experimental programmes and execute these in the laboratory.
- Lead the spray drying aspect of experimental programmes.
- Carry out the characterisation of the therapy using HPLC and other techniques.
- Develop protocols for the manufacture of the therapies.
- Ensure compliance to GLP is maintained at all times.
Required Skills & Expertise:
You will need:
- A PhD or MSc and subsequent experience in a relevant area of science
- Spray drying expertise either during your education or in a commercial environment
- Experience in the use of characterisation techniques such as HPLC.
The company are based in Mid Sussex and are committed to revolutionising how vaccines are made and taken by delivering them via capsule. They are leading the fight against COVID because their capsule can be delivered by post, simply swallowed, and achieves double immunity in one dose. However, this is their most recent development. To complement this, they have developed vaccines for the treatment of the Zika virus for example as well as developing thermally stable vaccines that can be delivered globally and hard to reach areas.
They are now continuing to target new viruses as well as other therapeutic areas that they are able to target as they continue to achieve their ambitions and realise the potential of this technology for the benefit of patients globally.